Hernia clinical trials at UCSF

2 research studies open to eligible people

A hernia is when part of an organ pushes through a weak spot in the body. UCSF is exploring a new treatment for severe diaphragmatic hernias in babies. They are also researching a mesh that could help strengthen abdominal surgery sites.

Showing trials for

  • Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)

    open to eligible females ages 18 years and up

    Despite advances in prenatal diagnosis and postnatal therapies, including ECMO (Extracorporeal Membrane Oxygenation), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with severe CDH remain high. The rationale for fetal therapy in severe CDH is to promote adequate lung growth for neonatal survival. Prenatal tracheal occlusion obstructs the normal egress of lung fluid during pulmonary development leading to increased lung tissue stretch, increased cell proliferation, and accelerated lung growth. The investigator's goal with this pilot study is to study the feasibility of implementing Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in the most severe group of fetuses with left CDH (LHR O/E < 25%).

    San Francisco, California

  • Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

    open to eligible people ages 18 years and up

    This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

    San Francisco, California and other locations

Our lead scientists for Hernia research studies include .

Last updated: